FDA Setback Triggers 50% Share Price Collapse
Corcept Therapeutics (NASDAQ: CORT) saw its stock price cut in half after a major regulatory setback at year-end 2025. On December 31, the company announced that the U.S. Food and Drug Administration (FDA) had declined to approve its new drug relacorilant for hypercortisolism (Cushing’s syndrome) ([1]) ([2]). The FDA issued a Complete Response Letter (CRL) stating it “could not arrive at a favorable benefit-risk assessment for relacorilant” without additional evidence of effectiveness ([1]) ([3]). This surprise rejection of Corcept’s once-promising cortisol-blocking drug – despite the pivotal trial meeting its primary endpoint – prompted an immediate selloff. By the close of that day, CORT shares had cratered roughly 50%, wiping out about half of the company’s market value ([1]) ([2]). Trading in the stock was even temporarily halted ahead of the announcement, underscoring the expectation of significant volatility when the news hit ([4]).
Management expressed shock at the FDA’s decision. CEO Joseph Belanoff said Corcept was “surprised and disappointed” by the outcome and remains determined to find a path forward for relacorilant ([3]) ([5]). The company plans to meet with the FDA as soon as possible to discuss next steps, but any favorable resolution will likely require new clinical trials and years of delay ([5]) ([2]). In effect, the CRL represents a major setback for Corcept’s growth plans, as relacorilant was expected to be a key future revenue driver. The final-day FDA rejection cast a shadow over what had been strong operating momentum for the company, and it set the stage for an uncertain 2026.
Market & Analyst Reactions to the CRL
Investors and analysts reacted swiftly and decisively to the relacorilant news. The stock’s massive one-day plunge was accompanied by unusually heavy trading volume and options activity, indicating many investors were scrambling to reduce exposure or bet on further downside ([4]). Put option buying surged, and analysts began re-pricing the company’s valuation in light of the approval uncertainty ([4]). For example, Wolfe Research responded by downgrading CORT to “Underperform” and slashing its price target to $30, citing a weaker revenue outlook and greater risk to the stock’s valuation after the FDA setback ([4]). Truist Securities echoed a cautious view, noting that FDA’s request for more data “may require additional trials, significantly dimming Corcept’s outlook in Cushing’s” ([2]). These tempered assessments reflect concern that relacorilant’s road to approval has become far lengthier and more expensive, undermining the bullish growth expectations that were priced into CORT shares.
The steep selloff also caught the attention of securities litigators. Within days, at least one shareholder rights law firm announced an investigation into whether Corcept had misled investors, signaling potential legal headaches ahead ([4]). It is not uncommon for such lawsuits to emerge after a drastic stock drop, and while these are still only allegations, they add to the cloud of uncertainty. Meanwhile, Corcept’s management faced questions about recent insider stock sales. Notably, CEO Belanoff had sold 40,000 shares at around $79 in early December, just weeks before the FDA decision was disclosed ([4]). Another insider also sold stock in the $79 range around the same time ([4]). These pre-plunge sales (which may have been under pre-arranged trading plans) nonetheless amplified negative market perception during the selloff ([4]). In sum, the investor reaction has been sharply negative – marked by a rapid loss of market capitalization, more bearish analyst coverage, and even legal and governance scrutiny in the wake of relacorilant’s rejection.
Business Fundamentals and Dividend Policy
Beyond the recent headlines, Corcept’s core business is a profitable specialty pharmaceutical operation focused on cortisol modulation. The company’s flagship product Korlym (mifepristone) has been on the market since 2012 as the first FDA-approved treatment for Cushing’s syndrome ([6]). Korlym has driven steady growth: in 2024, Corcept’s revenue reached a record $675.0 million, a 40% increase over 2023’s sales of $482.4 million ([7]) ([6]). Net income in 2024 was $141.2 million (about $1.23 per diluted share), up 33% from $106.1 million the prior year ([7]). This strong performance was attributed to a growing number of patients on Korlym and increased physician awareness of hypercortisolism’s prevalence ([7]) ([7]). However, Korlym’s success is a double-edged sword: it currently accounts for essentially all of Corcept’s revenue, leaving the company heavily reliant on a single product. The now-delayed relacorilant was intended to diversify and eventually succeed Korlym, underscoring the impact of the FDA setback on Corcept’s long-term growth narrative.
Corcept does not pay any dividend, opting instead to reinvest in R&D and return capital via share repurchases. The company has never declared a cash dividend, and its trailing twelve-month dividend payout is $0 (yield of 0.00%) ([8]). In fact, as of early 2026 Corcept’s dividend history remains blank, reflecting management’s focus on growth over income distribution. That said, Corcept has actively pursued stock buybacks as a way to return value to shareholders. In January 2024 – following its solid 2023 results – the Board authorized a stock repurchase program of up to $200 million of common stock, funded by the company’s substantial cash reserves ([6]) ([6]). Corcept repurchased shares throughout 2023 and 2024 under this and prior buyback programs, which contributed to a decline in total shares outstanding. These buybacks have been the primary mechanism of shareholder return, effectively a substitute for a dividend. Given the recent drop in share price, investors will be watching to see if Corcept accelerates repurchases to take advantage of the lower valuation – though the company must balance that against conserving cash for its pipeline needs.
Balance Sheet Strength and Leverage
One reassuring aspect for investors is Corcept’s solid balance sheet and conservative financial profile. The company amassed a cash and investments hoard of $603.2 million as of December 31, 2024 ([7]), thanks to years of profitable operations and relatively modest spending. This war chest provides a cushion to fund additional trials (such as any new studies required for relacorilant) or to weather potential headwinds like generic competition. Corcept carries minimal debt – effectively no long-term debt at the end of 2024 ([9]) – resulting in very low leverage. Its debt-to-equity ratio is a negligible 0.01, with a current ratio around 3.1 and quick ratio of 3.07, indicating ample liquidity to cover short-term obligations ([4]). In fact, Corcept’s interest expense is essentially zero, and it has been a net receiver of interest income due to its large cash investments ([10]) ([10]). This means traditional coverage ratios (like interest coverage) are a non-issue – the company’s operating earnings and cash easily cover its negligible interest burden. The sturdy balance sheet and lack of leverage give Corcept financial flexibility. It should be capable of absorbing increased R&D spending or a temporary earnings dip without jeopardy to its solvency. This strength is an important buffer as the company navigates the twin challenges of a delayed new product and forthcoming generic competition.
Valuation and Comparables Post-Plunge
Prior to the FDA news, CORT stock had rallied strongly on optimism about relacorilant and the company’s growth trajectory – at one point trading as high as ~$117 in the past year ([5]). That exuberance has been swiftly curtailed. After the ~50% crash, Corcept’s market capitalization stands near $3.5–$3.9 billion ([5]) ([4]) (down from roughly $7–$8 billion before the drop). In valuation terms, the stock is now priced around 5.5 times trailing sales (using 2024 revenues) and about 26–30 times trailing earnings. For instance, at a ~$3.66 billion market cap, Corcept’s price-to-earnings ratio is roughly 39 based on the last four reported quarters ([4]). Using 2024’s full-year diluted EPS of $1.23, the P/E comes out closer to 28 – still at the higher end for a mid-cap biopharma, but substantially lower than where it was pre-plunge. By comparison, other profitable biotech peers often trade in the 20–30x earnings range, so Corcept’s current valuation is not outlandish, assuming its earnings can be maintained. However, that assumption is debatable given the new uncertainties.
Bryce Paul's #1 Crypto To Buy — October 2025
It’s important to note that prior valuations had baked in significant future growth from relacorilant and other pipeline prospects. Analysts once projected that relacorilant (across Cushing’s and an oncology use) could drive multi-billion dollar annual revenue by the late 2020s ([11]). With that thesis in doubt, many are revisiting models and reducing forward estimates. If Korlym faces erosion (due to a generic entrant) and relacorilant’s contribution is delayed or denied, Corcept’s earnings in the next few years could actually decline. This downside scenario is likely why some analysts argue the stock is not yet “cheap” despite the halving in price ([4]). In effect, the E in the P/E is at risk – so a mid-20s multiple today might prove higher if earnings drop. On a price-to-book basis, CORT now trades near 7.5x book value (with ~$462 million equity reported at Q3 2025) ([12]) ([4]). Overall, Corcept’s valuation has reset to reflect a more mature, single-product biotech rather than a high-growth story. Any recovery in the stock will likely hinge on clarity around its pipeline and the competitive landscape, as current multiples appear to fairly balance the company’s solid profitability against its elevated risks.
Key Risks, Red Flags, and Uncertainties
Corcept now faces a convergence of strategic risks and red flags that investors must weigh. First and foremost is the imminent threat of generic competition to Korlym. The company’s Cushing’s franchise could be challenged by generic mifepristone much sooner than anticipated. In late 2023, Corcept lost a key patent infringement case against Teva Pharmaceutical regarding Korlym ([13]). Teva (and potentially others) have FDA-approved generic versions ready, and without patent protection, a generic launch could occur at any time ([12]) ([12]). Corcept has settled with one generic challenger (Hikma) to delay its entry until 2034 ([12]), but no such settlement exists with Teva. If Teva proceeds to market, Corcept would likely see a rapid erosion of Korlym sales as patients switch to a cheaper generic. Management could respond by cutting Korlym’s price or relying on brand loyalty/patient support programs, but a significant hit to revenue and margins would be likely. This overhang makes Corcept’s revenue guidance and financial outlook highly uncertain. (Notably, as of early 2025 the company was still forecasting aggressive growth – 2025 revenue guidance of $900–$950 million was issued before the CRL ([7]). That now looks optimistic if relacorilant is delayed and a Korlym generic enters the market.) Investors will be watching for updated guidance or commentary on how Corcept plans to defend its Cushing’s business.
Secondly, Corcept’s pipeline concentration risk has become more apparent. The company’s future was heavily tied to relacorilant, and the FDA’s rejection underscores the regulatory and clinical risk inherent in drug development. While relacorilant showed some efficacy in clinical trials, the FDA found the overall benefit-risk profile lacking ([3]) ([2]). It may take years of additional studies to address the agency’s concerns ([2]), and success is not guaranteed. Moreover, one FDA setback can raise questions about other uses of the drug – though relacorilant is also under FDA review for a form of ovarian cancer, that application (PDUFA target date July 11, 2026) will be scrutinized carefully ([3]). A second rejection would compound doubts about the molecule’s viability. Beyond relacorilant, Corcept’s pipeline includes earlier-stage compounds (such as dazucorilant for ALS and miricorilant for metabolic disorders) ([11]), but those are years from commercialization and carry their own development risks. In total, the company has discovered a large library of cortisol modulators and has multiple trials ongoing in areas like solid tumors, amyotrophic lateral sclerosis (ALS), and non-alcoholic steatohepatitis (NASH) ([6]). This broad pipeline could be a source of long-term value – but it also burns cash and may not yield near-term replacements for Korlym. The risk is that Corcept could face a gap period where Korlym revenues decline before any new product ramps up to profitability.
Several red flags have also emerged around Corcept’s governance and recent actions. The timing of large insider stock sales in late 2025 (just weeks before the CRL announcement) has drawn criticism ([4]) ([4]). While executives may sell for many reasons, the optics of the CEO liquidating shares at all-time highs only to have bad news follow is unfavorable. This could attract regulatory examination or shareholder lawsuits if any suggestion of insider knowledge arises. Additionally, the post-CRL legal investigation by Kaplan Fox (a law firm) signals that some investors suspect the company might have downplayed risks or withheld material information ([4]). Corcept did disclose the uncertainties around relacorilant’s approval in its filings and statements, but the dramatic market reaction suggests the bad outcome was not fully priced in. How management communicates and navigates these challenges will be critical for rebuilding trust. Another point to watch is Corcept’s use of cash – with over half a billion dollars in the bank, there is pressure to deploy it wisely. Aggressive stock buybacks at high prices (the company spent over $150 million on repurchases in the first half of 2023 alone, based on treasury stock changes ([10]) ([10])) could be questioned in hindsight if that cash is now needed for operations. Going forward, prioritizing R&D and defense of the core business over financial engineering will likely be viewed as more prudent given the circumstances.
Open Questions and Outlook
In the wake of the FDA rejection and stock plunge, several key questions hang over Corcept’s investment thesis. Foremost: Can relacorilant be salvaged, and on what timeline? Management insists it will continue pursuing approval for relacorilant in hypercortisolism ([5]) ([2]), but the path forward (e.g. additional trials’ design, endpoints, and duration) is yet to be determined. Investors will want clarity on how long it might take to gather “additional evidence of effectiveness” and whether the company will need to run a full new Phase 3 study. It’s possible that even in a best-case scenario, relacorilant’s U.S. approval for Cushing’s could be pushed out by several years, into 2027 or beyond. In the interim, will Corcept seek some form of conditional approval, explore use of the drug in narrower populations, or pivot resources to other pipeline assets? Similarly, what will be the fate of relacorilant’s oncology indication? The FDA’s concerns in Cushing’s may or may not foreshadow the decision in ovarian cancer (where the risk-benefit calculus could differ for a life-threatening condition). A positive approval in oncology in 2026 could provide a much-needed victory and new revenue stream, but after this setback, few are taking approval for granted.
Another open question is how Corcept will manage the Korlym franchise in the face of looming generics. Will the company consider a legal settlement with Teva to delay entry (as it did with Hikma) or perhaps license an authorized generic to retain some revenue? There is also the matter of pricing and patient access – Korlym is a costly orphan drug, and generic competition could significantly lower costs for patients and payers. Corcept’s revenue projections (which had assumed continued growth of Korlym sales) may need to be revised sharply downward if a generic arrives in 2024–2025. Investors will be looking for updates on this in the next earnings call or any new guidance. The company’s 2025 revenue guidance of $900+ million ([7]) is almost certainly going to be revisited, given that it assumed relacorilant approval and no generic erosion. If guidance is withdrawn or cut substantially, it could further impact sentiment. Conversely, if generics are kept at bay and Korlym sales hold up better than feared, that would bolster the bull case.
Corcept’s robust cash position raises the question of strategic moves. With ~$600 million in cash and no debt, the company has the capacity to invest in its pipeline or even consider acquisitions to diversify its portfolio. Will Corcept double down on its internal pipeline (e.g. accelerating trials for ALS or NASH programs), or might it seek external opportunities to reduce reliance on the cortisol pathway? Management’s track record has been to focus on their niche expertise in cortisol modulation. However, the current situation might warrant broader thinking – possibly bringing in partners for relacorilant or other programs to share risk, or acquiring complementary products. M&A interest could also emerge the other way around: Corcept’s depressed stock price and specialized Cushing’s business could attract a larger pharmaceutical company looking for a bolt-on acquisition (especially if relacorilant or the oncology program still hold promise). There are precedents of mid-size biotechs with one approved product being acquired when their pipelines hit bumps but their underlying technology is valuable. Whether Corcept is open to such possibilities remains to be seen; the founding CEO and team have led the company for decades, which may suggest a strong desire to remain independent.
Finally, a crucial question is how quickly can confidence be restored? The coming quarters will be pivotal for Corcept to demonstrate that it can navigate these challenges. Investors will be watching for updates from the FDA meetings, any signs of compromise or accelerated paths, and the company’s decisions on spending and capital allocation. The stock’s next moves will likely be driven by newsflow: positive surprises (such as a quicker resolution with the FDA or resilience in Korlym sales) could spark a rebound, while negative developments (e.g. an early Teva generic launch or additional regulatory setbacks) could lead to further declines. With CORT shares now trading around mid-$30s – roughly where they were two years ago – the company is at a crossroads. It has a proven product and profitable core business, but also faces significant headwinds and uncertainties. How Corcept’s leadership addresses these open questions will determine whether the recent plunge is remembered as a short-term overreaction or the start of a more prolonged collapse in investor confidence. For now, the investment community is in “wait-and-see” mode as the Corcept saga unfolds in 2026.
Sources: Corcept Therapeutics FDA complete response letter announcement ([3]) ([3]); Reuters coverage of FDA decision and stock plunge ([2]) ([2]); Motley Fool and Nasdaq reports on share price reaction ([1]) ([5]); Corcept 2024 earnings release ([7]) ([7]); AP News on patent dispute with Teva ([13]); DefenseWorld/MarketBeat on financial ratios and insider trades ([4]) ([4]); Corcept investor press releases on 2025 guidance and stock buyback program ([7]) ([6]).
Sources
- https://nasdaq.com/articles/why-corcept-therapeutics-plummeted-50-today
- https://pharma.economictimes.indiatimes.com/news/pharma-industry/us-fda-declines-to-approve-corcepts-drug-for-rare-hormonal-disorder/126316199
- https://biospace.com/press-releases/corcept-receives-complete-response-letter-for-relacorilant-as-a-treatment-for-patients-with-hypercortisolism
- https://defenseworld.net/2026/01/01/corcept-therapeutics-nasdaqcort-hits-new-12-month-low-following-analyst-downgrade.html
- https://fool.com/investing/2025/12/31/why-corcept-therapeutics-plummeted-by-50-today/
- https://biospace.com/corcept-therapeutics-provides-financial-update-and-announces-stock-repurchase-program
- https://ir.corcept.com/news-releases/news-release-details/corcept-therapeutics-announces-fourth-quarter-and-full-year-2024
- https://macrotrends.net/stocks/charts/CORT/corcept-therapeutics/dividend-yield-history
- https://macrotrends.net/stocks/charts/CORT/corcept-therapeutics/long-term-debt
- https://sec.gov/Archives/edgar/data/1088856/000162828023026768/cort-20230630.htm
- https://ainvest.com/news/cort-q2-earnings-beat-pipeline-momentum-case-revisiting-downside-buy-opportunity-2508/
- https://sec.gov/Archives/edgar/data/1088856/000162828023035988/cort-20230930.htm
- https://apnews.com/article/ab820b0c174cae958fc4af18eb56a7d2
For informational purposes only; not investment advice.